Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

China Stocks: China Shipbuilding, CSR, Shandong Lukang, Zoomlion

June 7 (Bloomberg) -- Shares of the following companies had unusual moves in China trading. Stock symbols are in parentheses and prices are as of the 3 p.m. close.

The Shanghai Composite Index, which tracks the bigger of China’s stock exchanges, gained 0.6 percent to 2,744.30. The CSI 300 Index advanced 0.6 percent to 3,004.26.

Medicine makers: Shandong Lukang Pharmaceutical Co. (600789 CH) jumped by the 10 percent daily limit to 8.75 yuan. PKU International Healthcare Group Southwest Pharmaceutical Co. (000788 CH) surged 10 percent to 9.96 yuan.

The Chinese antibiotics makers may benefit from demand for drugs treating E. coli bacteria infections, Hexun.com, an Internet news service, reported.

China Shipbuilding Industry Co. (601989 CH) rose 1.8 percent to 12.02 yuan, the highest close since May 25. The company plans to raise as much as 11.5 billion yuan ($1.8 billion) in a private sale of as many as 962 million shares for at least 11.96 yuan each. That compared with its previous plan announced on April 12 to issue as many as 1 billion shares.

Changsha Zoomlion Heavy Industry Science & Technology Development Co. (000157 CH) added 1.5 percent to 14.15 yuan, the first gain in three days. The company said its board approved an investment of 2.6 billion yuan to build production plants for cranes and excavators in Jiangyin, Jiangsu province.

CSR Corp. (601766 CH) climbed 3.5 percent to 6.85 yuan, the largest increase since May 9. The company estimated that its net profit rose more than 80 percent in the first six months compared with a year earlier.

Harbin Pharmaceutical Group Co. (600664 CH) retreated 2.8 percent to 17.29 yuan, its biggest loss since May 23. A plant belonging to the company’s parent, Harbin Pharmaceutical Group, was found to have caused air and water pollution, CCTV reported on June 5.

To contact Bloomberg News staff for this story: Irene Shen in Shanghai at Ishen4@bloomberg.net

To contact the editor responsible for this story: Darren Boey at dboey@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.